A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin.

Simple item page
dc.contributor.authorAnandh, Uen_US
dc.contributor.authorThomas, P Pen_US
dc.contributor.authorShastry, J Cen_US
dc.contributor.authorJacob, C Ken_US
dc.date.accessioned2000-11-20en_US
dc.date.accessioned2009-05-31T03:40:02Z
dc.date.available2000-11-20en_US
dc.date.available2009-05-31T03:40:02Z
dc.date.issued2000-11-20en_US
dc.description.abstractAIM: Intradermal administration of Hepatitis B vaccine (HBV) achieves better seroconversion in patients on dialysis compared to intramuscular administration. The aim of the study was to determine whether twice weekly intradermal injections of the vaccine can further augment the vaccine response as compared to once weekly injections. Patients with end stage renal failure on haemodialysis were randomly allocated over a period of 22 months to receive 20 mu gms of recombinant HBV by intradermal injections once a week (group 1) or twice a week (group 2) for 6 weeks. The patients recruited during the first 12 months of the study did not receive recombinant human erythropoietin (Epo) as it was not available (phase 1). During the last 10 months of study all patients received Epo (phase 2) in addition to HBV. RESULTS: A total of 85 patients were enrolled of whom 77 completed the study. There were 41 patients in group 1 and 36 patients in group 2. Seroprotection (anti HBs > 10 mIU/ml in the absence of HBs Ag and anti HBc) was achieved in 56.1% patients of group I compared to 77.8% of group 2 (p < 0.05). The seroprotection rate was 78.1% among patients receiving Epo (phase 2) compared to 60% among 45 who did not receive Epo (phase 1). Anti HBs titre in responders was 308.5 +/- 148.7 mIU/ml in patients of phase 2 compared to 198 +/- 112.8 mIU/ml in patients of phase 1 (p < 0.05). The subgroup receiving both Epo and twice weekly vaccine (group 2 of phase 2) had the highest seroprotection rate of 86.7%. CONCLUSION: Twice weekly intradermal vaccination is more effective than once weekly regime in achieving rapid seroconversion. The vaccine response may be augmented by use of Epo probably due to reduction in transfusion requirement and concomitant immunosuppression.en_US
dc.description.affiliationDepartment of Nephrology, Christian Medical College Hospital, Vellore, 632 004.en_US
dc.identifier.citationAnandh U, Thomas PP, Shastry JC, Jacob CK. A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. Journal of the Association of Physicians of India. 2000 Nov; 48(11): 1061-3en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/94097
dc.language.isoengen_US
dc.source.urihttps://www.japi.orgen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshErythropoietin --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B --drug therapyen_US
dc.subject.meshHepatitis B Antibodies --analysisen_US
dc.subject.meshHepatitis B Antigens --analysisen_US
dc.subject.meshHepatitis B Vaccines --administration & dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunity --physiologyen_US
dc.subject.meshInjections, Intradermalen_US
dc.subject.meshKidney Failure, Chronic --therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProbabilityen_US
dc.subject.meshReference Valuesen_US
dc.subject.meshRenal Dialysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Association of Physicians of India